ARIZONA COMMERCE AUTHORITY IS NOW ACCEPTING APPLICATIONS FOR THE 2021 ARIZONA INNOVATION CHALLENGE
Author Archive: AZBio
Governor Ducey Statement On Importance Of COVID-19 Vaccination
Governor Ducey: “Today, thanks to the miracle of modern science, we have something we didn’t have last year: a vaccine.”
Ivy Brain Tumor Center Announces Plan to Build New Global Headquarters in Phoenix
Facility Marks Largest Translational Research Center Dedicated to Brain Tumor Drug Development and Treatment Worldwide
HTG Forms New Drug Discovery Business Unit
New unit to focus on development of drug candidates through use of HTG Transcriptome PanelContinue reading
Opportunity Alert: Flinn Foundation Translational Research Seed Grants Program
The Flinn Foundation will fund up to 10 research teams focused on advancing new products or services to address a compelling clinical need during the next round of its Translational Research Seed Grants Program.Continue reading
TGen Looks Beyond COVID-19 as it Advances Pathogen Sequencing
Genomic analysis of SARS-CoV-2, aided by seqWell’s technology, increases sequencing output by 10-fold
Lilly and Banner Alzheimer’s Institute collaborate on planned Phase 3 prevention trial of donanemab
Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease Continue reading
Like priming a pump, changes in cells damaged by chronic lung disease can result in severe COVID
Results from a TGen-led international study suggest that SARS-CoV-2 takes advantage of genetic changes among patients with pre-existing lung diseasesContinue reading
TGen study suggests a variety of factors beyond age influence reaction time
Reaction time helps measure healthy vs. diseased brains, revealing potential connections tied to the risk of Alzheimer’s disease and dementiaContinue reading
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.Continue reading